Program

 

Tuesday 22 MayWednesday 23 MayThursday 24 May
 

TUESDAY, MAY 22, 2018

 
  OPENING SESSION
 
  16:00

Opening of the workshop by the Conference chair

 
 Session 1: New technologies and formulations
Chairs: t.b.c.
 
  16:15How to End the Global HCV Epidemic - the role of injectables
David Thomas, MD
 
  16:45Clinical Development of Long-Acting Broadly Neutralizing Monoclonal Antibodies: Lessons Learned Thus Far
Richard Koup, MD
 
  17:15Viral Dynamics and the Search for an HIV Cure 
Steven Becker, MD
 
  17:45Discussion 
   
 18:00Welcome Reception 
   
 POSTER VIEWING - SESSION I
 
  Back to top 
 

WEDNESDAY, MAY 23, 2018

 
 Session 2: Hepatitis related topic
Chairs: t.b.c.
 
  8:30The use of DAA’s in pregnancy in HCV infected mothers
David Burger, PharmD
 
  9:00Clinical case presentation
David Thomas, MD
 
  9:30

Tenofovir exposure during pregnancy and postpartum in hepatitis B mono-infected women on TDF monotherapy compared to HIV-infected women on TDF-containing antiretroviral therapy

Colbers 

 1
  9:45

Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir

Jimmerson

 2
  10:00

A Pharmacometabolomics Approach for Predicting Tenofovir diphosphate (TFV-DP) Concentrations in Dried Blood Spots (DBS)

Ibrahim

 3
  10:15Discussion 
   
 10:30Coffee Break 
   
 Session 3: Round Table discussion: validation of Physiologically based pharmacokinetic (PBPK) modeling
Chairs: t.b.c. 
 
  11:00Application of Physiologically based pharmacokinetic (PBPK) Modelling to Drug Development Decisions
Joga Gobburu, PhD, MBA 
 
  11:20Application of PBPK modelling for assessment of DDI liability in combination therapies
Karen Yeo, PhD
 
  11:40Physiologically based pharmacokinetic modeling and simulation in drug product development and review 
Xinyuan Zhang, PhD
 
  12:00Panel Discussion 
   
 12:30Lunch Break 
   
 Session 4: Towards Precision Medicine 
Moderators: t.b.c.
 
  14:00How/when will pharmacogenomics translate into improved clinical care?
David Haas, MD
 
  14:30Last advances in HIV pharmacogenomics 
Andrea Calcagno, MD
 
  15:00

SLC22a2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptoms in hiv-positive patients on dolutegravir

Borghetti

 4
  15:15

Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations

Calcagno

 5
   
 15:30Tea Break 
   
 SHORT POSTER PRESENTATIONS; "BEST OF POSTERS"
 
  

Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling

Freriksen

 14
  

Does hepatic impairment affect the exposure of monoclonal antibodies? 

Qin

 15
  

Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy

Haaland

 16
  

Elvitegravir pharmacokinetics during Pregnancy and Postpartum

Colbers

 17
   
 Session 5: HIV related topic
Chairs: t.b.c.
 
 16:30Clinical Pharmacology of Integrase Inhibitors 
Giovanni di Perri, MD, PhD
 
 17:00Clinical case presentation 
Marta Boffito, PhD
 
 17:30

Bictegravir/Emtricitabine/Tenofovir Alafenamide Phase 3 Exposure-Response Analysis of Safety and Efficacy in the Treatment of HIV Infection

Lutz 

 6
 17:45

Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon

Le

 7
 18:00

First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women

Colbers

 8
   
 18:15Workshop Dinner 
 Back to top 
 

THURSDAY, MAY 24, 2018

 
 Session 6: Drug - Drug interactions related session
Chairs: t.b.c.
 
 8:30

Update on DDI guidelines of the FDA - in vitro

Xinning Yang

 
 8:50

Update on DDI guidelines of the FDA - in vivo

Kellie Reynolds

 
 9:10

Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda

Seden

 9
 9:25

Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception

Scarsi

 10
 9:40

Pharmacokinetics of dolutegravir 100 mg once-daily with rifampicin

Wang

 11
 9:55

Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure following Oral Co-administration

Ford

 12
 10:10

Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir

 Rawizza

 13
   
 10:25Coffee Break 
   
 10:55

Clinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now

Craig Hendrix

 
   
 SHORT POSTER PRESENTATIONS "BEST OF POSTERS" 
 
  

Comparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients. 

Le

 18
  

Polypharmacy, drug-drug interactions and potentially inappropriate prescribing in elderly patients of the swiss HIV cohort study 

Marzolini

 19
  

Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years

Ibrahim

 20
  

Differential brain tissue penetration of antiretrovirals and fluconazole

Nicol

 21
   
 ROUND TABLE DISCUSSION: TWO-DRUG REGIMENS
Moderator: Giovanni di Perri
Panel members: Jonathan Schapiro / Saye Khoo
 
  11:55A Round Table Discussion 
   
 CLOSING THE CONFERENCE
 
  12:40Closing of the conference by Conference Chair 
 Back to top